Table 1.
Association Between AR Expression and Clinicopathological Characteristics of Patients with Gastric Cancer
| Clinical Variables | Total Patients: N (%) | Evaluable Patients: N (%) | ||
|---|---|---|---|---|
| 60 (100) | Overexpressed N (%) | Underexpressed N (%) | P | |
| Age (years) median, range | 63, 33–83 | |||
| N <63 | 29 (48.3) | 18 (30) | 11 (18.3) | 0.465 |
| N ≥63 | 31 (51.7) | 22 (36.7) | 9 (15) | |
| Sex | ||||
| Male | 39 (65) | 26 (43.3) | 13 (21.7) | 1.000 |
| Female | 21 (35) | 14 (23.3) | 7 (11.7) | |
| Tumor size (cm) | ||||
| N <5 | 17 (28.3) | 9 (15) | 8 (13.3) | 0.156 |
| N ≥ 5 | 43 (71.7) | 31 (51.7) | 12 (20) | |
| Lauren’s classification | ||||
| Intestinal | 55 (91.7) | 36 (60) | 19 (31.7) | 0.656 |
| Diffuse | 5 (8.3) | 4 (6.7) | 1 (1.7) | |
| Tumor grade | ||||
| Poorly differentiated | 33 (55) | 21 (35) | 12 (20) | |
| Moderately differentiated | 21 (35) | 15 (25) | 6 (10) | 0.919 |
| Well differentiated | 6 (10) | 4 (6.7) | 2 (3.3) | |
| Tumor type | ||||
| Adenocarcinoma | 46 (76.7) | 29 (48.3) | 17 (28.3) | 0.347 |
| Signet ring cell carcinoma | 14 (23.3) | 11 (18.3) | 3 (5) | |
| Lymphovascular invasion | ||||
| Yes | 43 (71.7) | 33 (55) | 10 (16.7) | 0.008* |
| No | 17 (28.3) | 7 (11.7) | 10 (16.7) | |
| Perineural invasion | ||||
| Yes | 50 (83.3) | 33 (55) | 17 (28.3) | 1.000 |
| No | 10 (16.7) | 7 (11.7) | 3 (5) | |
| Tumor shape | ||||
| Ulcerated flat | 48 (80) | 31 (51.7) | 17 (28.3) | |
| Linitis plastica | 5 (8.3) | 4 (6.7) | 1 (1.7) | 0.887 |
| Polypoid | 7 (11.7) | 5 (8.3) | 2 (3.3) | |
| Tumor location | ||||
| Proximal | 28 (46.7) | 17 (28.3) | 11 (18.3) | |
| Middle | 22 (36.7) | 15 (25) | 7 (11.7) | 0.589 |
| Distal | 6 (10) | 4 (6.7) | 2 (3.3) | |
| Diffuse | 4 (6.7) | 4 (6.7) | 0 (0) | |
| T classificationa | ||||
| pT1 | 0 (0) | 0 (0) | 0 (0) | |
| pT2 | 13 (18.3) | 7 (11.7) | 6 (10) | 0.001* |
| pT3 | 19 (31.7) | 8 (13.3) | 11 (18.3) | |
| pT4 | 28 (46.7) | 25 (41.7) | 3 (5) | |
| N classificationa | ||||
| N0 | 19 (31.7) | 8 (13.3) | 11 (18.3) | |
| N1 | 11 (18.3) | 7 (11.7) | 4 (6.7) | 0.002* |
| N2 | 17 (28.3) | 15 (25) | 2 (3.3) | |
| N3 | 13 (21.7) | 10 (16.7) | 3 (5) | |
| M classificationa | ||||
| M0 | 42 (70) | 24 (40) | 18 (30) | 0.019* |
| M1 | 18 (30) | 16 (26.7) | 2 (3.3) | |
| TNM stagea | ||||
| I+II | 22 (36.7) | 10 (16.7) | 12 (20) | |
| III+IV | 38 (63.3) | 30 (50) | 8 (13.3) | 0.008* |
Notes: aThe 8th TNM Classification of Malignant Tumors proposed by the AJCC/UICC. *P<0.05 values are statistically significant.
Abbreviation: AR, androgen receptor.